MARKET

ADGI

ADGI

ADAGIO THERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.70
+0.44
+8.37%
After Hours: 5.68 -0.02 -0.35% 19:58 01/14 EST
OPEN
5.08
PREV CLOSE
5.26
HIGH
5.90
LOW
4.920
VOLUME
7.83M
TURNOVER
--
52 WEEK HIGH
78.82
52 WEEK LOW
4.920
MARKET CAP
634.13M
P/E (TTM)
-9.4700
1D
5D
1M
3M
1Y
5Y
30 Stocks Moving In Friday's Mid-Day Session
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.
Benzinga · 2d ago
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 3d ago
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron variant.
Benzinga · 3d ago
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday.
Benzinga · 3d ago
BRIEF-Adagio Therapeutics Summarizes Adg20 Neutralizing Activity Against Sars-Cov-2 Variants And Outlines Initiatives To Address Omicron
reuters.com · 4d ago
Adagio soars 25% as studies suggest ADG20 neutralization activity against Omicron
Adagio Therapeutics (NASDAQ:ADGI) said three separate publications that show that its lead monoclonal antibody (mAb) ADG20 has neutralization activity against the Omicron (B.1.1.529) variant of SARS-CoV-2, and outlined initiatives to address
Seekingalpha · 4d ago
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway to Address Omicron and Potential Future SARS-CoV-2 Varia...
GlobeNewswire · 4d ago
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pand...
GlobeNewswire · 01/06 11:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADGI. Analyze the recent business situations of ADAGIO THERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
75.00%Hold
25.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADGI stock price target is 8.33 with a high estimate of 10.00 and a low estimate of 6.00.
High10.00
Average8.33
Low6.00
Current 5.70
EPS
Actual
Estimate
-0.82-0.62-0.41-0.21
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 64
Institutional Holdings: 46.51M
% Owned: 41.81%
Shares Outstanding: 111.25M
TypeInstitutionsShares
Increased
0
0
New
64
46.51M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Co-Founder/Director
Rene Russo
Chief Executive Officer/Co-Founder/Director
Tillman Gerngross
Chief Financial Officer/Primary Contact
Jane Henderson
Chief Operating Officer
David Hering
Chief Technology Officer
Rebecca Dabora
Other
Jill Andersen
Other
Lynn Connolly
Other
Elham Hershberger
Director
Ellen Marram
Director
Terrance McGuire
Director
Redonda Miller
Director
Ajay Royan
Independent Director
Tomas Heyman
Independent Director
Howard Mayer
Independent Director
Anand Shah
Independent Director
Michael Wyzga
No Data
About ADGI
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.

Webull offers kinds of Adagio Therapeutics Inc stock information, including NASDAQ:ADGI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADGI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADGI stock methods without spending real money on the virtual paper trading platform.